Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420498 · ClinicalTrials.gov registry record · Phase 2
Effects of Atomoxetine on Cognitive Function in Schizophrenia
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00420498 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 12 participants.
The verdict
NCT00420498, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of atomoxetine (Strattera™) on prefrontal cognitive functioning in persons with schizophrenia. Secondarily, the effects of atomoxetine on positive and negative symptoms and on cigarette smoking consumption in persons with schizophrenia will be examined.
Interventions
- DRUG Atomoxetine (Strattera™)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420498
The ClinicalTrials.gov registry entry for NCT00420498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine (Strattera™) is the first listed.
NCT00420498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420498 about?
NCT00420498 is a clinical study titled "Effects of Atomoxetine on Cognitive Function in Schizophrenia". The purpose of this study is to examine the effects of atomoxetine (Strattera™) on prefrontal cognitive functioning in persons with schizophrenia. Secondarily, the effects of atomoxetine on positive and negative symptoms and on cigarette smoking consumption in persons with schizophrenia will be exam...
What is the current status of trial NCT00420498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2005-08. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00420498?
The interventions under investigation include: Atomoxetine (Strattera™) (DRUG).
Who is sponsoring clinical trial NCT00420498?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.